TheraRadar
← Back
Data updated: Nov 8, 2026

PHARMAZONE

Generics

PHARMAZONE is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.

1964
Since
126
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
1 Small Molecules

PHARMAZONE's Key Drugs

PHARMAZONE's core commercial portfolio centers on PRASUGREL, OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

PHARMAZONE's Therapeutic Areas

PHARMAZONE's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 42%
14 drugs
Neurology 18%
6 drugs
Infectious Disease 15%
5 drugs
Immunology 15%
5 drugs
Respiratory 9%
3 drugs

PHARMAZONE Pipeline Snapshot

Active clinical trials for PHARMAZONE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • PRASUGREL leads revenue
  • • 4 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling